Physician profile
Beth A Walker
NPI 1790920494
$4,061.49
in general payments reported to CMS, 2019-2025
25 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $875 · 2022: $1,204 · 2023: $951 · 2024: $576 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,982.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $715.79 | 2021-2023 | Farxiga, Fasenra, Brilinta |
| Abbvie INC. | $460.86 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $417.77 | 2021-2025 | Spravato |
| Evoke Pharma, INC. | $215.16 | 2022-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $197.46 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.32 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $166.74 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $159.13 | 2022-2023 | Crysvita |
| Boston Scientific Corporation | $145.65 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $132.59 | 2024 | |
| Angiodynamics, INC. | $129.17 | 2023 | Auryon Laser System 100-120 Vac |
| Mylan Specialty L.P. | $124.99 | 2024 | Yupelri |
| Mayne Pharma Commercial LLC | $124.74 | 2023 | |
| Phathom Pharmaceuticals, INC. | $121.98 | 2025 | Voquezna |
| Genzyme Corporation | $120.58 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $107.10 | 2022 | |
| Agile Therapeutics, INC. | $105.82 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.25 | 2022 | |
| Corcept Therapeutics | $100.00 | 2024 | Korlym |
| Gilead Sciences, INC. | $92.99 | 2021 | |
| Novartis Pharmaceuticals Corporation | $70.42 | 2023 | |
| Exeltis, USA INC. | $30.53 | 2025 | Twirla, Slynd |
| E.R. Squibb & Sons, L.L.C. | $17.40 | 2021 | |
| Esperion Therapeutics, INC. | $14.40 | 2021 | |
| Merck Sharp & Dohme LLC | $13.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.